162 related articles for article (PubMed ID: 36332495)
21. Expression of heat shock protein 70 and 27 in non-small cell lung cancer and its clinical significance.
Huang Q; Zu Y; Fu X; Wu T
J Huazhong Univ Sci Technolog Med Sci; 2005; 25(6):693-5. PubMed ID: 16696328
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of resistance to chemotherapy in non-small cell lung cancer.
Min HY; Lee HY
Arch Pharm Res; 2021 Feb; 44(2):146-164. PubMed ID: 33608812
[TBL] [Abstract][Full Text] [Related]
23. Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach.
Chatterjee S; Burns TF
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28914774
[TBL] [Abstract][Full Text] [Related]
24. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors.
Rolfo C; Giovannetti E; Hong DS; Bivona T; Raez LE; Bronte G; Buffoni L; Reguart N; Santos ES; Germonpre P; Taron M; Passiglia F; Van Meerbeeck JP; Russo A; Peeters M; Gil-Bazo I; Pauwels P; Rosell R
Cancer Treat Rev; 2014 Sep; 40(8):990-1004. PubMed ID: 24953979
[TBL] [Abstract][Full Text] [Related]
25. Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer.
Eltayeb K; La Monica S; Tiseo M; Alfieri R; Fumarola C
Cells; 2022 Jan; 11(3):. PubMed ID: 35159223
[TBL] [Abstract][Full Text] [Related]
26. The Effect of Afatinib Treatment in Non-small Cell Lung Cancer Cells.
Pancewicz-Wojtkiewicz J; Bernatowicz PL
Anticancer Res; 2017 Jul; 37(7):3543-3546. PubMed ID: 28668844
[TBL] [Abstract][Full Text] [Related]
27. Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy.
Lelj-Garolla B; Kumano M; Beraldi E; Nappi L; Rocchi P; Ionescu DN; Fazli L; Zoubeidi A; Gleave ME
Mol Cancer Ther; 2015 May; 14(5):1107-16. PubMed ID: 25740245
[TBL] [Abstract][Full Text] [Related]
28. An intronic polymorphism in GRP78 improves chemotherapeutic prediction in non-small cell lung cancer.
Zhu X; Lin MCM; Fan W; Tian L; Wang J; Ng SS; Wang M; Kung H; Li D
Chest; 2012 Jun; 141(6):1466-1472. PubMed ID: 21940774
[TBL] [Abstract][Full Text] [Related]
29. Heat Shock Proteins (HSPs): A Novel Target for Cancer Metastasis Prevention.
Narayanankutty V; Narayanankutty A; Nair A
Curr Drug Targets; 2019; 20(7):727-737. PubMed ID: 30526455
[TBL] [Abstract][Full Text] [Related]
30. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
31. [Resistances to targeted therapies and strategy for following therapeutic lines in metastatic NSCLC].
Brosseau S; Oulkhouir Y; Naltet C; Zalcman G
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S27-33. PubMed ID: 26118873
[TBL] [Abstract][Full Text] [Related]
32. MicroRNAs and Heat Shock Proteins in Breast Cancer Biology.
Yildiz MT; Tutar L; Giritlioğlu NI; Bayram B; Tutar Y
Methods Mol Biol; 2022; 2257():293-310. PubMed ID: 34432285
[TBL] [Abstract][Full Text] [Related]
33. Visfatin mediates doxorubicin resistance in human non-small-cell lung cancer via Akt-mediated up-regulation of ABCC1.
Cao Z; Liang N; Yang H; Li S
Cell Prolif; 2017 Oct; 50(5):. PubMed ID: 28762597
[TBL] [Abstract][Full Text] [Related]
34. Falnidamol and cisplatin combinational treatment inhibits non-small cell lung cancer (NSCLC) by targeting DUSP26-mediated signal pathways.
Cui Z; Li D; Zhao J; Chen K
Free Radic Biol Med; 2022 Apr; 183():106-124. PubMed ID: 35278641
[TBL] [Abstract][Full Text] [Related]
35. Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations.
Choi SK; Kim M; Lee H; Kwon Y; Cha HJ; Jang SJ; Na Y; Lee YS
Cell Oncol (Dordr); 2022 Oct; 45(5):913-930. PubMed ID: 35931945
[TBL] [Abstract][Full Text] [Related]
36. The functional role of long non-coding RNAs and their underlying mechanisms in drug resistance of non-small cell lung cancer.
Zhou H; Feng B; Abudoureyimu M; Lai Y; Lin X; Tian C; Huang G; Chu X; Wang R
Life Sci; 2020 Nov; 261():118362. PubMed ID: 32871184
[TBL] [Abstract][Full Text] [Related]
37. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
Bao R; Lai CJ; Wang DG; Qu H; Yin L; Zifcak B; Tao X; Wang J; Atoyan R; Samson M; Forrester J; Xu GX; DellaRocca S; Borek M; Zhai HX; Cai X; Qian C
Mol Cancer Ther; 2009 Dec; 8(12):3296-306. PubMed ID: 19952121
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of MEOX2 and TWIST1 is associated with H3K27me3 levels and determines lung cancer chemoresistance and prognosis.
Ávila-Moreno F; Armas-López L; Álvarez-Moran AM; López-Bujanda Z; Ortiz-Quintero B; Hidalgo-Miranda A; Urrea-Ramírez F; Rivera-Rosales RM; Vázquez-Manríquez E; Peña-Mirabal E; Morales-Gómez J; Vázquez-Minero JC; Téllez-Becerra JL; Ramírez-Mendoza R; Ávalos-Bracho A; de Alba EG; Vázquez-Santillán K; Maldonado-Lagunas V; Santillán-Doherty P; Piña-Sánchez P; Zúñiga-Ramos J
PLoS One; 2014; 9(12):e114104. PubMed ID: 25460568
[TBL] [Abstract][Full Text] [Related]
39. Role of metabolic reprogramming in drug resistance to epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer.
Wu Y; Gao W; Liu H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 May; 46(5):545-551. PubMed ID: 34148892
[TBL] [Abstract][Full Text] [Related]
40. GRP78, intronic polymorphisms, and pharmacogenomics in non-small cell lung cancer.
Merrick DT
Chest; 2012 Jun; 141(6):1377-1378. PubMed ID: 22670016
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
